Drugs / ACI-7104.056
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06015841 | Jul 2023 → Jan 2028 expected | autosomal recessive early-onset Parkinson disease 6 | AC Immune SA | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-12-11 | AC Immune SA | Results AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease acimmune.com ↗
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkinson’s disease (PD). |
| 2025-04-30 | AC Immune SA | Results AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update acimmune.com ↗
Our interim Phase 2 data on ACI-7104.056, our wholly owned a-syn active immunotherapy, demonstrated strong immunogenicity and a favorable safety profile in early Parkinson’s disease patients, further supporting its best-in-class characteristics. |
| 2025-04-02 | AC Immune SA | Results AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease acimmune.com ↗ |
| 2024-11-14 | AC Immune SA | Results AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease acimmune.com ↗ |
| 2024-02-22 | AC Immune SA | Results AC Immune Announces Upcoming Presentations at AD/PD™ 2024 acimmune.com ↗
ACI-7104.056, an active immunotherapy for synucleinopathies, induces a strong and sustained antibody response against alpha-synuclein in non-human primates |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACI-7104.056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06015841 ↗ |
| Modality | Vaccine | “The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.” NCT06015841 ↗ |
| Route | Intramuscular | “The route of administration of the study treatment and placebo will be by intramuscular injections.” NCT06015841 ↗ |